SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Winther Kristensen Bjarne)
 

Sökning: WFRF:(Winther Kristensen Bjarne) > Postoperative neoad...

  • Malmström, AnnikaLinköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, LAH Linköping (författare)

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial

  • Artikel/kapitelEngelska2017

Förlag, utgivningsår, omfång ...

  • TAYLOR & FRANCIS LTD,2017
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-144005
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-144005URI
  • https://doi.org/10.1080/0284186X.2017.1332780DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-143564URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Merck; Linkoping University Hospital for Neuro-research; Lions Cancer Foundation; Cancer Foundation Norrland, Umea, Sweden; LIUCancer; South-East Sweden FORSS
  • Introduction: A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We therefore investigated neoadjuvant TMZ (NeoTMZ) in a randomized trial. During enrollment, concomitant and adjuvant radio-chemotherapy with TMZ became standard treatment. The trial was amended to include concurrent TMZ.Patients and methods: Patients, after surgery for GBM or AA, age 60 years and performance status (PS) 0-2, were randomized to either 2-3 cycles of TMZ, 200mg/m(2) days 1-5 every 28 days, followed by RT 60Gy in 30 fractions or RT only. Patients without progressive disease after two TMZ cycles, received the third cycle. From March 2005, TMZ 75mg/m(2) was administered daily concomitant with RT. TMZ was recommended first-line treatment at progression. Primary endpoint was overall survival and secondary safety.Results: The study closed prematurely after enrolling 144 patients, 103 with GBM and 41 with AA. Median age was 53 years (range 24-60) and 89 (62%) were male. PS was 0-1 for 133 (92%) patients, 53 (37%) had complete surgical resection and 18 (12%) biopsy. Ninety-two (64%) received TMZ concomitant with RT. Seventy-two (50%) were randomized to neoadjuvant treatment. For the overall study population survival was 20.3 months for RT and 17.7 months for NeoTMZ (p=.76), this not reaching the primary objective. For the preplanned subgroup analysis, we found that NeoTMZ AA patients had a median survival of 95.1 months compared to 35.2 months for RT (p=.022). For patients with GBM, no difference in survival was observed (p=.10). MGMT and IDH status affected outcome.Conclusions: No advantage of NeoTMZ was noted for the overall study population or subgroup of GBM, while NeoTMZ resulted in 5 years longer median survival for patients diagnosed as AA.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Skovgaard Poulsen, HansRigshosp, Denmark (författare)
  • Henning Gronberg, BjornNorwegian University of Science and Technology, Norway; Trondheim Regional and University Hospital, Norway (författare)
  • Stragliotto, GiuseppeKarolinska University Hospital, Sweden (författare)
  • Hansen, SteinbjornUniversity of Southern Denmark, Denmark (författare)
  • Asklund, ThomasKarolinska University Hospital, Sweden; Umeå University, Sweden (författare)
  • Holmlund, BirgittaLinköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US(Swepub:liu)birho30 (författare)
  • Lysiak, MalgorzataLinköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten(Swepub:liu)mally72 (författare)
  • Dowsett, JosephUniversity of Southern Denmark, Denmark (författare)
  • Winther Kristensen, BjarneUniversity of Southern Denmark, Denmark (författare)
  • Söderkvist, PeterLinköpings universitet,Avdelningen för cellbiologi,Medicinska fakulteten,Region Östergötland, Klinisk patologi och klinisk genetik(Swepub:liu)petso43 (författare)
  • Rosell, JohanLinköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Regionalt Cancercentrum(Swepub:liu)johro19 (författare)
  • Henriksson, RogerUmeå universitet,Onkologi,Umeå University, Sweden; Regional Cancer Centre Stockholm Gotland, Sweden(Swepub:umu)rohe0003 (författare)
  • Linköpings universitetAvdelningen för cellbiologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Acta Oncologica: TAYLOR & FRANCIS LTD56:12, s. 1776-17850284-186X1651-226X

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy